|1.||Baldari, Sergio: 2 articles (07/2015 - 06/2015)|
|2.||Buscombe, John R: 2 articles (01/2010 - 01/2008)|
|3.||Behr, T M: 2 articles (01/2009 - 04/2003)|
|4.||Höffken, H: 2 articles (01/2009 - 04/2003)|
|5.||Gratz, S: 2 articles (01/2009 - 04/2003)|
|6.||Massaro, Arianna: 2 articles (11/2008 - 04/2008)|
|7.||Rubello, Domenico: 2 articles (11/2008 - 04/2008)|
|8.||Cattelan, Anna Maria: 2 articles (11/2008 - 04/2008)|
|9.||Rampin, Lucia: 2 articles (11/2008 - 04/2008)|
|10.||Banti, Elena: 2 articles (11/2008 - 04/2008)|
01/01/2004 - "In particular, an improvement in specificity using protocol B was found in those patients with infection and with only a mild LeukoScan uptake in the early 4 h imaging: in these patients an increasing uptake intensity pattern observed in the delayed 24 h imaging was indicative of infection while a decreasing pattern suggested a negative result. "
08/01/2002 - "This study suggests that Leukoscan can be used successfully to image orthopaedic infection, with its greatest strength being a high negative predictive accuracy. "
01/01/2010 - "Tc-99m sulesomab is indicated in bone and joint infection, but reading of scans can be affected by pre-existing conditions. "
11/01/2008 - "Although the dual-time LeukoScan is capable of significantly increasing specificity for detecting infection. "
11/01/2008 - "An increase in the intensity of uptake of at least one scale-step at visual analysis and 20% at semiquantitative ROI analysis at the dual-time (early vs. delayed) LeukoScan was considered consistent with infection, whereas a stable or decreasing pattern was judged a negative result. "
09/01/2004 - "In pediatric patients with suspected nonclassic appendicitis, management decisions incorporating sulesomab imaging provided benefit in separating surgical from nonsurgical patients."
09/01/2004 - "In 78% of patients, sulesomab accurately detected or excluded acute appendicitis and would have changed management plans. "
09/01/2004 - "Sulesomab imaging had 95% sensitivity, 90% specificity, 95% negative predictive value, and 90% positive predictive value for acute appendicitis. "
09/01/2004 - "Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent."
03/01/1999 - "Management decisions incorporating sulesomab imaging potentially provide clear patient benefits, especially by correctly predicting surgery to be unnecessary in 97% of patients without acute appendicitis."
01/01/2003 - "(a) Sulesomab does not localize in inflammation as a result of binding to circulating granulocytes; (b) sulesomab is cleared into inflammation nonspecifically via increased vascular permeability; nevertheless, it may be cleared after local binding to primed granulocytes or bind to activated, migrated extravascular granulocytes; and (c) HSA produces a similar or higher T/Bkg ratio than sulesomab because sulesomab is cleared into normal tissues and because image positivity in inflammation is significantly dependent on local blood-pool expansion."
11/01/2001 - "In pediatric IBD assessment, planar imaging with Sulesomab did not prove very sensitive in detecting inflammation in each bowel segment. "
04/01/2005 - "In several patients, imaging with Sulesomab was able to rule out osteomyelitis, helping to avoid useless antibiotic therapy and its associated side effects."
08/01/2000 - "In this small series, LEUKOSCAN scintigraphy was found to be less specific for the diagnosis of osteomyelitis than HMPAO-LS. "
06/01/1999 - "Diabetic patients suspected of having osteomyelitis secondary to foot ulcers underwent scintigraphic imaging with Sulesomab, an anti-granulocyte antibody Fab' fragment labeled with technetium-99m. "
06/01/1999 - "Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy."
06/01/1999 - "Among 122 patients who had osteomyelitis confirmed or excluded by histopathologic and/or microbiologic techniques, Sulesomab had a 91% sensitivity, a 56% specificity, and an accuracy of 80%. "
|5.||Soft Tissue Infections
01/01/2008 - "To perform a retrospective review of all patients receiving technetium-99m ((99m)Tc)-labelled sulesomab over a 4-year period to determine if soft tissue infections can be accurately identified. "
04/01/2003 - "The aim of the current study was to determine the overall diagnostic accuracy of Tc-99m-labeled antigranulocyte monoclonal antibody Fab' fragments (LeukoScan) for the routine detection of bone and soft tissue infections in a retrospective evaluation. "
01/01/2008 - "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections."
08/01/2000 - "In addition, the interpretation of LEUKOSCAN scintigraphy is more difficult than HMPAO-LS for the diagnosis of bone infection in the diabetic foot, and would appear to be less discriminating for differentiating soft tissue infection from osteitis in the case of plantar perforating ulcers."
04/01/2003 - "138 patients (63 men, 75 women; mean age, 58.29 +/- 25.38 years) with fever of unknown origin and possible endocarditis (n = 59), infection of arthroplastic joints (n = 20), arthritis (n = 16), peripheral (n = 15) and central bone infections (n = 14), soft tissue infection (n = 6), appendicitis (n = 4), pericarditis (n = 2), or vascular graft infection (n = 2) underwent imaging after injection of 555 to 925 MBq (15 to 25 mCi) Tc-99m-labeled antigranulocyte monoclonal antibody Fab' fragments (LeukoScan). "
|1.||Technetium (Technetium 99m)
|2.||Immunoglobulin Fab Fragments
|3.||monoclonal antibody IMMU-MN3 (Sulesomab)
|4.||Technetium Tc 99m Exametazime (Ceretec)
|7.||N-(2-naphthalene)sulfonyl-DL-tryptophan (A 91)
|2.||Prostheses and Implants (Prosthesis)
|4.||Deep Brain Stimulation